P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)

• Masoom Priyadarshini,
• Gaurav Deshpande,
• Simran K Tiwana,
• T. Kim Le,
• Sean Garrison,
• Farrukh Awan

Affiliations

Masoom Priyadarshini

1 Bristol Myers Squibb, Princeton, United States

Gaurav Deshpande

1 Bristol Myers Squibb, Princeton, United States

Simran K Tiwana

1 Bristol Myers Squibb, Princeton, United States

T. Kim Le

1 Bristol Myers Squibb, Princeton, United States

Sean Garrison

1 Bristol Myers Squibb, Princeton, United States

Farrukh Awan

2 University of Texas Southwestern Medical Center, Dallas, United States